{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:41Z","timestamp":1778889761745,"version":"3.51.4"},"reference-count":28,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited standard therapeutic options and poor outcomes. PBL typically lacks expression of the B-cell antigens CD20 or CD19 and, accordingly, has not benefited from the incorporation of B-cell\u2013targeted antibodies. However, recent reports demonstrate that B-cell maturation antigen (BCMA) is expressed in most patients with PBL. BCMA is an established therapeutic target in multiple myeloma. Herein, we describe the clinical course of 3 patients with PBL found to express BCMA by immunohistochemistry who were treated with the BCMA\u00d7CD3 bispecific antibody teclistamab after developing disease refractory to at least 2 lines of standard therapy. A complete response was observed in 2 patients: 1 patient remains in remission after 2 years of teclistamab treatment, while the second achieved a complete response after 1 cycle of teclistamab, subsequently underwent allogeneic stem cell transplantation, and developed relapsed PBL 3 months post-transplant. The third patient developed a small bowel obstruction and transitioned to hospice care after 1 cycle of teclistamab. This case series adds to the growing evidence that BCMA is expressed in a considerable subset of patients with PBL and suggests that BCMA may serve as a potential molecular biomarker in PBL for further investigation of available BCMA-directed therapies.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7119","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:45:11Z","timestamp":1771519511000},"page":"128-131","source":"Crossref","is-referenced-by-count":1,"title":["Targeting BCMA in Plasmablastic Lymphoma With Teclistamab: A Case Study of Three Patients"],"prefix":"10.6004","volume":"24","author":[{"given":"Joseph M.","family":"Cannova","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Wool","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Blood","first-page":"1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","author":"Delecluse HJ","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F,  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413\u20131420."},{"key":"B2","series-title":"Blood","first-page":"2323","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo JJ","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015;125:2323\u20132330."},{"key":"B3","series-title":"EJHaem","first-page":"285","article-title":"B-cell maturation antigen expression and clinical features of plasmablastic lymphoma","volume":"5","author":"Dong N","year":"2024","unstructured":"Dong N, Zhang H, Song J,  B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem 2024;5:285\u2013289."},{"key":"B4","series-title":"Blood","first-page":"573","article-title":"Improving outcomes in plasmablastic lymphoma: a multicenter experience from an American cohort","volume":"144","author":"Hamby M","year":"2024","unstructured":"Hamby M, Egleston B, Frosch Z,  Improving outcomes in plasmablastic lymphoma: a multicenter experience from an American cohort. Blood 2024;144(Suppl 1):Abstract 573."},{"key":"B5","series-title":"Blood","first-page":"152","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio PR","year":"2024","unstructured":"Di Ciaccio PR, Polizzotto MN, Cwynarski K,  The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood 2024;143:152\u2013165."},{"key":"B6","series-title":"Ann Hematol","first-page":"667","article-title":"Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele PL","year":"2016","unstructured":"Fedele PL, Gregory GP, Gilbertson M,  Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol 2016;95:667\u2013668."},{"key":"B7","series-title":"Leuk Lymphoma","first-page":"2121","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus C","year":"2018","unstructured":"Dittus C, Grover N, Ellsworth S,  Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma 2018;59:2121\u20132127."},{"key":"B8","series-title":"Br J Haematol","first-page":"679","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F,  Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 2019;184:679\u2013682."},{"key":"B9","series-title":"N Engl J Med","first-page":"235","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J,  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235\u2013242."},{"key":"B10","series-title":"Blood Cancer J","first-page":"27","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi A","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 2024;14:27."},{"key":"B11","series-title":"N Engl J Med","first-page":"2531","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL,  Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531\u20132544."},{"key":"B12","series-title":"Lancet","first-page":"665","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani SZ","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ,  Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398:665\u2013674."},{"key":"B13","series-title":"N Engl J Med","first-page":"335","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K,  Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335\u2013347."},{"key":"B14","series-title":"J Immunother Cancer","first-page":"e006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan S","year":"2023","unstructured":"Raghunandan S, Pauly M, Blum WG,  BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. J Immunother Cancer 2023;11:e006684."},{"key":"B1","series-title":"Blood","first-page":"1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","author":"Delecluse HJ","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F,  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413\u20131420."},{"key":"B2","series-title":"Blood","first-page":"2323","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo JJ","year":"2015","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015;125:2323\u20132330."},{"key":"B3","series-title":"EJHaem","first-page":"285","article-title":"B-cell maturation antigen expression and clinical features of plasmablastic lymphoma","volume":"5","author":"Dong N","year":"2024","unstructured":"Dong N, Zhang H, Song J,  B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem 2024;5:285\u2013289."},{"key":"B4","series-title":"Blood","first-page":"573","article-title":"Improving outcomes in plasmablastic lymphoma: a multicenter experience from an American cohort","volume":"144","author":"Hamby M","year":"2024","unstructured":"Hamby M, Egleston B, Frosch Z,  Improving outcomes in plasmablastic lymphoma: a multicenter experience from an American cohort. Blood 2024;144(Suppl 1):Abstract 573."},{"key":"B5","series-title":"Blood","first-page":"152","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio PR","year":"2024","unstructured":"Di Ciaccio PR, Polizzotto MN, Cwynarski K,  The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood 2024;143:152\u2013165."},{"key":"B6","series-title":"Ann Hematol","first-page":"667","article-title":"Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele PL","year":"2016","unstructured":"Fedele PL, Gregory GP, Gilbertson M,  Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol 2016;95:667\u2013668."},{"key":"B7","series-title":"Leuk Lymphoma","first-page":"2121","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus C","year":"2018","unstructured":"Dittus C, Grover N, Ellsworth S,  Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma 2018;59:2121\u20132127."},{"key":"B8","series-title":"Br J Haematol","first-page":"679","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F,  Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 2019;184:679\u2013682."},{"key":"B9","series-title":"N Engl J Med","first-page":"235","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier B","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J,  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235\u2013242."},{"key":"B10","series-title":"Blood Cancer J","first-page":"27","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi A","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 2024;14:27."},{"key":"B11","series-title":"N Engl J Med","first-page":"2531","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL,  Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531\u20132544."},{"key":"B12","series-title":"Lancet","first-page":"665","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani SZ","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ,  Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 2021;398:665\u2013674."},{"key":"B13","series-title":"N Engl J Med","first-page":"335","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel J","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K,  Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 2023;389:335\u2013347."},{"key":"B14","series-title":"J Immunother Cancer","first-page":"e006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan S","year":"2023","unstructured":"Raghunandan S, Pauly M, Blum WG,  BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. J Immunother Cancer 2023;11:e006684."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p128.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p128.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p128.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:29Z","timestamp":1773318689000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p128.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7119","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}